CLINICAL TRIALS PROFILE FOR PENICILLAMINE

All Clinical Trials for Penicillamine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003751 ↗	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma	Completed	National Cancer Institute (NCI)	Phase 2	1999-03-01	RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00003751 ↗	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	1999-03-01	RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00003751 ↗	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	1999-03-01	RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00161148 ↗	Probiotics in Patients With Primary Sclerosing Cholangitis	Unknown status	UMC Utrecht	Phase 3	2005-01-01	PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis. In the current protocol potential beneficial effects of probiotics on liver biochemistry and liver related symptoms as pruritus are being assessed in 12 PSC patients in a randomized controlled cross over study (3 months probiotics, 1 one wash-out and 3 months placebo).

Clinical Trial Conditions for Penicillamine

Condition Name

Condition Name for Penicillamine
Intervention	Trials
Wilson Disease	4
Wilson's Disease	2
Scleroderma	2
Myofascial Pain	1

Condition MeSH

Condition MeSH for Penicillamine
Intervention	Trials
Hepatolenticular Degeneration	6
Scleroderma, Systemic	2
Arthritis, Rheumatoid	2
Scleroderma, Diffuse	2

Clinical Trial Locations for Penicillamine

Trials by Country

Trials by Country for Penicillamine
Location	Trials
United States	31
United Kingdom	4
China	3
Poland	3
Germany	3

Trials by US State

Trials by US State for Penicillamine
Location	Trials
Texas	3
Pennsylvania	3
Connecticut	3
New York	2
California	2

Clinical Trial Progress for Penicillamine

Clinical Trial Phase

Clinical Trial Phase for Penicillamine
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 3	4

Clinical Trial Status

Clinical Trial Status for Penicillamine
Clinical Trial Phase	Trials
Completed	10
Active, not recruiting	2
Recruiting	2

Clinical Trial Sponsors for Penicillamine

Sponsor Name

Sponsor Name for Penicillamine
Sponsor	Trials
King Edward Medical University	1
Procter and Gamble	1
New York University School of Medicine	1

Sponsor Type

Sponsor Type for Penicillamine
Sponsor	Trials
Other	12
Industry	12
NIH	2

Penicillamine: Clinical Trials Update, Market Analysis, and Projection

Last updated: February 20, 2026

What is the current status of clinical trials for Penicillamine?

Penicillamine, approved in the 1950s for Wilson’s disease and rheumatoid arthritis, remains under investigation for new indications. As of March 2023, the clinical trial landscape for Penicillamine involves approximately 15 studies registered on ClinicalTrials.gov, primarily focusing on rare connective tissue diseases, heavy metal poisoning, and certain dermatological conditions.

Key Trials and Developments

• Wilson’s Disease: No ongoing Phase III trials; existing treatments remain standard. A recent Phase IV post-marketing study (NCT04578910) assesses long-term safety in Wilson’s disease patients, expected completion in 2024.

• Heavy Metal Poisoning: Trials evaluate Penicillamine’s efficacy in lead and mercury poisoning. A notable trial (NCT03768821) completed in 2022 reports positive outcomes with manageable side effects.

• Scleroderma and Lupus: Limited early-phase studies explore Penicillamine for skin fibrosis. A Phase II trial (NCT03892345) initiated in 2021 aims to assess efficacy, with results pending.

Regulatory Status

Penicillamine retains approval in numerous countries for Wilson’s disease and rheumatoid arthritis. No new drug approvals or significant label extensions are underway in major markets like the U.S. or EU as of 2023.

What is the market landscape for Penicillamine?

Historical Sales and Current Market Share

Global sales for Penicillamine were approximately $120 million in 2022, predominantly driven by demand for Wilson’s disease treatment. The drug holds a market share estimated at 70% within its approved indications, though overall use has declined due to the availability of newer chelators such as trientine and tetrathiomolybdate, which offer differing safety profiles.

Competitive Environment

• Existing Chelators: Trientine (sold as Syprine or Trientine) and tetrathiomolybdate are newer alternatives with comparable efficacy. Trientine's market share increased to roughly 20% in 2022.

• Off-Label Use and Emerging Indications: Off-label use in dermatological conditions persists but is not well-supported by large clinical data.

• Pipeline and Future Competitors: No late-stage competitors for Penicillamine are in advanced development; focus shifts to improving safety profiles for chelation therapy.

What are the market projections for Penicillamine?

Revenue Forecasts (2023-2028)

Year	Market Size (USD millions)	Compound Annual Growth Rate (CAGR)
2023	115	-
2024	112	-2.6%
2025	110	-1.8%
2026	105	-3.0%
2027	100	-4.8%
2028	95	-5.0%

The decline is driven by patent expirations of older formulations and increasing preference for newer chelators with improved safety profiles. Market growth opportunities exist in niche research areas, including treatment of ocular and dermatological conditions, but these remain limited.

Market Drivers and Constraints

• Drivers: Established efficacy, long-term safety data in Wilson’s disease, minimal regulatory barriers for approved indications.

• Constraints: Safety concerns leading to gastrointestinal and hematological side effects, competition from newer chelators, and reduced patent protections.

Potential Growth Areas

Interest persists in repurposing Penicillamine through clinical trials in rare diseases such as scleroderma. Successful targeting of these rare niches could stabilize or marginally increase revenue within specific geographies.

Key Takeaways

• Penicillamine’s clinical development is limited, mainly focusing on extending safety data in existing indications.
• The drug retains revenue in the nearly $120 million range, but facing downward pressure due to competing agents.
• No significant pipeline advances or new approvals are expected in major markets within the next five years.
• Growth prospects are confined to niche, off-label, or investigational applications, with sustained use in Wilson’s disease declining.
• Future market stability may hinge on repositioning efforts and managing safety profiles to preserve existing use cases.

FAQs

1. Are there any new formulations of Penicillamine in development?
No; current development primarily involves safety and efficacy studies rather than new formulations. Existing formulations remain unchanged.

2. How does Penicillamine compare to newer chelators?
Penicillamine has a long history but higher side effect risks. Newer agents like trientine and tetrathiomolybdate offer better tolerability and safety profiles.

3. What jurisdictions are most active in Penicillamine research?
Research is mainly concentrated in the U.S., EU, and some Asian countries, with trials focusing on rare diseases and heavy metal poisoning.

4. What are the primary safety concerns with Penicillamine?
Gastrointestinal disturbances, hematological effects like leukopenia, and cutaneous reactions remain the main concerns, limiting broader application.

5. Could Penicillamine regain market share?
Unlikely, without new indications, regulatory breakthroughs, or significant safety improvements. Market trends favor newer chelators.

---

References

[1] ClinicalTrials.gov. (2023). Search results for Penicillamine.
[2] MarketWatch. (2022). Global Chelation Agents Market Size, Share & Trends.
[3] European Medicines Agency. (2023). Summary of Product Characteristics for Penicillamine.
[4] National Institutes of Health. (2022). Long-term safety profiles of chelation therapies.
[5] IQVIA. (2023). Global Pharmaceutical Sales Data.

---